AI
BNTC icon

Atom Investors’s Benitec Biopharma BNTC Stock Holding History

Atom Investors’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$650K Sell
48,591
-3,872
-7% -$45.9K 0.06% 489
2026
Q1 		$559K Buy
+52,463
New +$607K 0.04% 458
2022
Q2 		– Sell
-2,196
Closed -$87K – 259
2022
Q1 		$87K Buy
+2,196
New +$91K 0.04% 177

Other funds holding BNTC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return

Atom Investors's BNTC Position: Q2 2026 in Review

Atom Investors reduced its Benitec Biopharma (BNTC) stake by 7.4% in Q2 2026, selling an estimated $45.9K and leaving 48,591 shares worth $650K. The position accounts for 0.06% of the portfolio, ranked #489.

Atom Investors first reported a position in BNTC in Q1 2022 and has held it in 3 quarters since. 87 funds tracked by Wall St. Rank hold BNTC as of Q2 2026.

  • Atom Investors held 48,591 shares of Benitec Biopharma worth $650K as of Q2 2026.
  • Atom Investors sold 3,872 Benitec Biopharma shares in Q2 2026, an estimated $45.9K.
  • Benitec Biopharma made up 0.06% of Atom Investors's portfolio in Q2 2026, its #489 holding.
  • Atom Investors first reported a position in Benitec Biopharma in Q1 2022 and has held it in 3 quarters since.
  • 87 funds tracked by Wall St. Rank held Benitec Biopharma as of Q2 2026.

Based on Atom Investors's 13F filing for Q2 2026, filed 14 Aug 2026.